Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group

Stephen D. Williams, John A. Blessing, Kenneth D Hatch, Howard D. Homesley

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced dysgerminoma.

Original languageEnglish (US)
Pages (from-to)1950-1955
Number of pages6
JournalJournal of Clinical Oncology
Volume9
Issue number11
StatePublished - Nov 1991
Externally publishedYes

Fingerprint

Dysgerminoma
Drug Therapy
Cisplatin
Consolidation Chemotherapy
Vinblastine
Bleomycin
Dactinomycin
Vincristine
Etoposide
Cyclophosphamide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Williams, S. D., Blessing, J. A., Hatch, K. D., & Homesley, H. D. (1991). Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group. Journal of Clinical Oncology, 9(11), 1950-1955.

Chemotherapy of advanced dysgerminoma : Trials of the gynecologic oncology group. / Williams, Stephen D.; Blessing, John A.; Hatch, Kenneth D; Homesley, Howard D.

In: Journal of Clinical Oncology, Vol. 9, No. 11, 11.1991, p. 1950-1955.

Research output: Contribution to journalArticle

Williams, SD, Blessing, JA, Hatch, KD & Homesley, HD 1991, 'Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group', Journal of Clinical Oncology, vol. 9, no. 11, pp. 1950-1955.
Williams, Stephen D. ; Blessing, John A. ; Hatch, Kenneth D ; Homesley, Howard D. / Chemotherapy of advanced dysgerminoma : Trials of the gynecologic oncology group. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 11. pp. 1950-1955.
@article{f2ebfb6f702c49ff8ee9e21bdf1db8bf,
title = "Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group",
abstract = "Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced dysgerminoma.",
author = "Williams, {Stephen D.} and Blessing, {John A.} and Hatch, {Kenneth D} and Homesley, {Howard D.}",
year = "1991",
month = "11",
language = "English (US)",
volume = "9",
pages = "1950--1955",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Chemotherapy of advanced dysgerminoma

T2 - Trials of the gynecologic oncology group

AU - Williams, Stephen D.

AU - Blessing, John A.

AU - Hatch, Kenneth D

AU - Homesley, Howard D.

PY - 1991/11

Y1 - 1991/11

N2 - Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced dysgerminoma.

AB - Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced dysgerminoma.

UR - http://www.scopus.com/inward/record.url?scp=0026005129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026005129&partnerID=8YFLogxK

M3 - Article

C2 - 1719142

AN - SCOPUS:0026005129

VL - 9

SP - 1950

EP - 1955

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -